Clinical Trial Update: Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of pathogen-inactivated platelets stored for up to seven days in patients with thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thrombocytopenia

Drugs mentioned

• INTERCEPT Platelets (amotosalen-treated platelets)

Snippet

Sponsor: Cerus Corporation | Conditions: Thrombocytopenia | Phase 3 | Status: COMPLETED